Secret London is a Facebook group started by 21-year-old Bristol University graduate, Tiffany Philippou, on 19 January 2010 in response to a Saatchi & Saatchi competition. The group grew rapidly (180,000 members as of 8 February 2010) and is composed mostly of Londoners who use the site to share suggestions and photos of London. After the group's early success, the founder announced her intention to launch a website of the same name by crowdsourcing the design and development. The website was launched on 16 February 2010. == Other secret cities == Following the initial success of Secret London, a number of other secret groups were independently started around the world, some of which already have over 100,000 users. As of 19 February 2010, the list of other groups includes: Secret Frankfurt, Secret Tel Aviv, Secret Paris, Secret New York, Secret Tokyo, Secret Toronto, Secret Los Angeles, Secret Exeter, Secret Boston, Secret Norwich, Secret Singapore, Secret Brighton, Secret Minneapolis, Secret Sydney, Secret Canberra, Secret Brisbane, Secret Wellington, Secret Christchurch, Secret Madeira, Secret Funchal, Secret Bristol and Secret Cardiff. == Controversy == Some commentators have questioned whether it possible to share secrets without compromising them, and whether sharing tips publicly will lead to over-exposure of the businesses who are recommended.
Point distribution model
The point distribution model is a model for representing the mean geometry of a shape and some statistical modes of geometric variation inferred from a training set of shapes. == Background == The point distribution model concept has been developed by Cootes, Taylor et al. and became a standard in computer vision for the statistical study of shape and for segmentation of medical images where shape priors really help interpretation of noisy and low-contrasted pixels/voxels. The latter point leads to active shape models (ASM) and active appearance models (AAM). Point distribution models rely on landmark points. A landmark is an annotating point posed by an anatomist onto a given locus for every shape instance across the training set population. For instance, the same landmark will designate the tip of the index finger in a training set of 2D hands outlines. Principal component analysis (PCA), for instance, is a relevant tool for studying correlations of movement between groups of landmarks among the training set population. Typically, it might detect that all the landmarks located along the same finger move exactly together across the training set examples showing different finger spacing for a flat-posed hands collection. == Details == First, a set of training images are manually landmarked with enough corresponding landmarks to sufficiently approximate the geometry of the original shapes. These landmarks are aligned using the generalized procrustes analysis, which minimizes the least squared error between the points. k {\displaystyle k} aligned landmarks in two dimensions are given as X = ( x 1 , y 1 , … , x k , y k ) {\displaystyle \mathbf {X} =(x_{1},y_{1},\ldots ,x_{k},y_{k})} . It's important to note that each landmark i ∈ { 1 , … k } {\displaystyle i\in \lbrace 1,\ldots k\rbrace } should represent the same anatomical location. For example, landmark #3, ( x 3 , y 3 ) {\displaystyle (x_{3},y_{3})} might represent the tip of the ring finger across all training images. Now the shape outlines are reduced to sequences of k {\displaystyle k} landmarks, so that a given training shape is defined as the vector X ∈ R 2 k {\displaystyle \mathbf {X} \in \mathbb {R} ^{2k}} . Assuming the scattering is gaussian in this space, PCA is used to compute normalized eigenvectors and eigenvalues of the covariance matrix across all training shapes. The matrix of the top d {\displaystyle d} eigenvectors is given as P ∈ R 2 k × d {\displaystyle \mathbf {P} \in \mathbb {R} ^{2k\times d}} , and each eigenvector describes a principal mode of variation along the set. Finally, a linear combination of the eigenvectors is used to define a new shape X ′ {\displaystyle \mathbf {X} '} , mathematically defined as: X ′ = X ¯ + P b {\displaystyle \mathbf {X} '={\overline {\mathbf {X} }}+\mathbf {P} \mathbf {b} } where X ¯ {\displaystyle {\overline {\mathbf {X} }}} is defined as the mean shape across all training images, and b {\displaystyle \mathbf {b} } is a vector of scaling values for each principal component. Therefore, by modifying the variable b {\displaystyle \mathbf {b} } an infinite number of shapes can be defined. To ensure that the new shapes are all within the variation seen in the training set, it is common to only allow each element of b {\displaystyle \mathbf {b} } to be within ± {\displaystyle \pm } 3 standard deviations, where the standard deviation of a given principal component is defined as the square root of its corresponding eigenvalue. PDM's can be extended to any arbitrary number of dimensions, but are typically used in 2D image and 3D volume applications (where each landmark point is R 2 {\displaystyle \mathbb {R} ^{2}} or R 3 {\displaystyle \mathbb {R} ^{3}} ). == Discussion == An eigenvector, interpreted in euclidean space, can be seen as a sequence of k {\displaystyle k} euclidean vectors associated to corresponding landmark and designating a compound move for the whole shape. Global nonlinear variation is usually well handled provided nonlinear variation is kept to a reasonable level. Typically, a twisting nematode worm is used as an example in the teaching of kernel PCA-based methods. Due to the PCA properties: eigenvectors are mutually orthogonal, form a basis of the training set cloud in the shape space, and cross at the 0 in this space, which represents the mean shape. Also, PCA is a traditional way of fitting a closed ellipsoid to a Gaussian cloud of points (whatever their dimension): this suggests the concept of bounded variation. The idea behind PDMs is that eigenvectors can be linearly combined to create an infinity of new shape instances that will 'look like' the one in the training set. The coefficients are bounded alike the values of the corresponding eigenvalues, so as to ensure the generated 2n/3n-dimensional dot will remain into the hyper-ellipsoidal allowed domain—allowable shape domain (ASD).
Biohybrid system
Biohybrid systems refer to the integration of biological materials, such as cells or tissues, with artificial components, including electronics or mechanical structure. This combination incorporates the capabilities of living organisms with the precision of man-made technology. As a result, these systems perform tasks that neither biology nor machines could achieve independently. Biohybrid systems might use lab-cultured muscle cells to power small robots or combine sensors with living tissue for better health sensing. The intent behind these systems is to combine the benefits of biological and technological components to introduce new solutions for complex medical challenges. Biohybrid systems may have transformative potential across sectors, such as robotics to create actuators and sensors that mimic natural muscle and nerve function, medicine in developing smart implants and drug delivery systems, in prosthetics for enhancing user control through neural or muscular interfaces and environmental sustainability for deploying biohybrid solutions for pollution sensing or remediation. == Origin == The term "biohybrid" is a compound of "bio" from biology (meaning life) and "hybrid" (referring to a combination of distinct elements), denoting a field of study. Its use helps distinguish such systems from purely biological constructs or entirely synthetic machines. Early academic mentions may include bio actuated robotics papers and foundational tissue-robot integration studies published in journals like Nature Biotechnology or Science Robotics. The emergence of the term reflects a growing recognition of the need to describe systems that do not fit cleanly into traditional categories. == Design principles == One of the most significant biohybrid challenges is to engineer interfaces between living tissue and artificial materials that are efficient. This means having precise control over adhesion at the surface, diffusion of nutrients, and signal conduction. Actuation mechanisms within the heart of these systems generate movement or mechanical response. These may be in the form of living muscle cells such as skeletal myocytes or cardiomyocytes, soft pneumatic actuators, or electrical stimulation-responsive tissues. Materials selection is equally critical. Hydrogels, elastomers like PDMS (polydimethylsiloxane), and biopolymers are commonly used due to their softness and biocompatibility. These materials must support cell viability, resist immune attack, and allow the integration of mechanical or electrical components. == Key components == At their core, biohybrid systems work by bridging living biological parts with technology. Through this integration, functionality that neither system could accomplish singularly is possible. Biological parts may be cells, tissues, or even organs—occasionally cultured in a laboratory setting. These biological parts carry out biologically inspired behaviors, such as muscle contraction or chemical sensing in the body. Technological components may constitute devices like sensors, electronic components, and mechanical structure. These manipulate the system, supply power, or transfer data. An example is a sensor that is implantable within a body and detects glucose levels as it sends information to a smart phone. By integrating these artificial and biological parts, biohybrid systems can perform advanced functions, such as tissue regeneration, real-time health monitoring, or the recovery of motor function in paralysis patients. Biohybrid systems generally consist of two major components: the biological and the mechanical. Biological components may include muscle cells for contraction, endothelial cells for vascularization, and stem cells for regenerative capabilities. Mechanical components comprise soft actuators that mimic organic motion, synthetic scaffolds that provide support and structure, and microfluidic systems that facilitate the delivery of nutrients and removal of waste. These components are combined in a manner that allows for dynamic, lifelike behavior—such as the contraction of tissue or the propagation of mechanical waves—while maintaining biocompatibility and durability. == Applications == The range of applications for biohybrid systems is broad and continuously expanding. In robotics, biohybrid structures have been used to engineer microscopic, muscle-driven machines, such as Harvard University's biohybrid stingray robot. In medical applications, they offer new alternatives for organ repair and augmentation, including biohybrid heart valves and esophageal scaffolds. Biohybrids are also promising in neural interfaces, where the goal is to create long-lasting, stable interaction between mechanical devices and brain tissue. Muscle-actuated drug response platforms are under exploration in pharmacology for modelling and real-time screening. == Examples == Several high-profile research projects have demonstrated the potential of biohybrid systems: Harvard researchers developed a biohybrid swimming ray powered by rat cardiac cells layered onto a gold skeleton, mimicking the motion of a real stingray. At the Massachusetts Institute of Technology, a cardiac pump actuated entirely by living heart muscle cells was engineered to simulate the behavior of a beating heart. Bio actuated soft robots have been built to simulate gut peristalsis, using muscle contractions to replicate natural wave-like movement in the digestive tract. == Challenges and limitations == As with many technologies that involve living systems, biohybrid systems raise important ethical and biomedical questions. Cell sourcing remains a key issue, particularly when embryonic or animal-derived cells are used. Long-term viability is another concern—living tissues must be kept alive with nutrients and oxygen, and they often degrade or elicit immune responses when implanted. Powering these biological parts presents logistical and ethical hurdles as well. Systems must either include internal mechanisms for nutrient delivery or be supported externally, which can limit portability and independence. == Future directions == Researchers are exploring self-directed, self-regulated organ substitutes and regenerative implants that can respond to their surroundings in real-time. These systems may be integrated with artificial intelligence to make them adjust to stimuli and coordinate complex behaviors. Future potential applications are wearable biohybrid systems for rehabilitation, space medicine devices for long-duration missions, and implantable devices that integrate into human physiology.
Equalized odds
Equalized odds, also referred to as conditional procedure accuracy equality and disparate mistreatment, is a measure of fairness in machine learning. A classifier satisfies this definition if the subjects in the protected and unprotected groups have equal true positive rate and equal false positive rate, satisfying the formula: P ( R = + | Y = y , A = a ) = P ( R = + | Y = y , A = b ) y ∈ { + , − } ∀ a , b ∈ A {\displaystyle P(R=+|Y=y,A=a)=P(R=+|Y=y,A=b)\quad y\in \{+,-\}\quad \forall a,b\in A} For example, A {\displaystyle A} could be gender, race, or any other characteristics that we want to be free of bias, while Y {\displaystyle Y} would be whether the person is qualified for the degree, and the output R {\displaystyle R} would be the school's decision whether to offer the person to study for the degree. In this context, higher university enrollment rates of African Americans compared to whites with similar test scores might be necessary to fulfill the condition of equalized odds, if the "base rate" of Y {\displaystyle Y} differs between the groups. The concept was originally defined for binary-valued Y {\displaystyle Y} . In 2017, Woodworth et al. generalized the concept further for multiple classes.
Learnable function class
In statistical learning theory, a learnable function class is a set of functions for which an algorithm can be devised to asymptotically minimize the expected risk, uniformly over all probability distributions. The concept of learnable classes are closely related to regularization in machine learning, and provides large sample justifications for certain learning algorithms. == Definition == === Background === Let Ω = X × Y = { ( x , y ) } {\displaystyle \Omega ={\mathcal {X}}\times {\mathcal {Y}}=\{(x,y)\}} be the sample space, where y {\displaystyle y} are the labels and x {\displaystyle x} are the covariates (predictors). F = { f : X ↦ Y } {\displaystyle {\mathcal {F}}=\{f:{\mathcal {X}}\mapsto {\mathcal {Y}}\}} is a collection of mappings (functions) under consideration to link x {\displaystyle x} to y {\displaystyle y} . L : Y × Y ↦ R {\displaystyle L:{\mathcal {Y}}\times {\mathcal {Y}}\mapsto \mathbb {R} } is a pre-given loss function (usually non-negative). Given a probability distribution P ( x , y ) {\displaystyle P(x,y)} on Ω {\displaystyle \Omega } , define the expected risk I P ( f ) {\displaystyle I_{P}(f)} to be: I P ( f ) = ∫ L ( f ( x ) , y ) d P ( x , y ) {\displaystyle I_{P}(f)=\int L(f(x),y)dP(x,y)} The general goal in statistical learning is to find the function in F {\displaystyle {\mathcal {F}}} that minimizes the expected risk. That is, to find solutions to the following problem: f ^ = arg min f ∈ F I P ( f ) {\displaystyle {\hat {f}}=\arg \min _{f\in {\mathcal {F}}}I_{P}(f)} But in practice the distribution P {\displaystyle P} is unknown, and any learning task can only be based on finite samples. Thus we seek instead to find an algorithm that asymptotically minimizes the empirical risk, i.e., to find a sequence of functions { f ^ n } n = 1 ∞ {\displaystyle \{{\hat {f}}_{n}\}_{n=1}^{\infty }} that satisfies lim n → ∞ P ( I P ( f ^ n ) − inf f ∈ F I P ( f ) > ϵ ) = 0 {\displaystyle \lim _{n\rightarrow \infty }\mathbb {P} (I_{P}({\hat {f}}_{n})-\inf _{f\in {\mathcal {F}}}I_{P}(f)>\epsilon )=0} One usual algorithm to find such a sequence is through empirical risk minimization. === Learnable function class === We can make the condition given in the above equation stronger by requiring that the convergence is uniform for all probability distributions. That is: The intuition behind the more strict requirement is as such: the rate at which sequence { f ^ n } {\displaystyle \{{\hat {f}}_{n}\}} converges to the minimizer of the expected risk can be very different for different P ( x , y ) {\displaystyle P(x,y)} . Because in real world the true distribution P {\displaystyle P} is always unknown, we would want to select a sequence that performs well under all cases. However, by the no free lunch theorem, such a sequence that satisfies (1) does not exist if F {\displaystyle {\mathcal {F}}} is too complex. This means we need to be careful and not allow too "many" functions in F {\displaystyle {\mathcal {F}}} if we want (1) to be a meaningful requirement. Specifically, function classes that ensure the existence of a sequence { f ^ n } {\displaystyle \{{\hat {f}}_{n}\}} that satisfies (1) are known as learnable classes. It is worth noting that at least for supervised classification and regression problems, if a function class is learnable, then the empirical risk minimization automatically satisfies (1). Thus in these settings not only do we know that the problem posed by (1) is solvable, we also immediately have an algorithm that gives the solution. == Interpretations == If the true relationship between y {\displaystyle y} and x {\displaystyle x} is y ∼ f ∗ ( x ) {\displaystyle y\sim f^{}(x)} , then by selecting the appropriate loss function, f ∗ {\displaystyle f^{}} can always be expressed as the minimizer of the expected loss across all possible functions. That is, f ∗ = arg min f ∈ F ∗ I P ( f ) {\displaystyle f^{}=\arg \min _{f\in {\mathcal {F}}^{}}I_{P}(f)} Here we let F ∗ {\displaystyle {\mathcal {F}}^{}} be the collection of all possible functions mapping X {\displaystyle {\mathcal {X}}} onto Y {\displaystyle {\mathcal {Y}}} . f ∗ {\displaystyle f^{}} can be interpreted as the actual data generating mechanism. However, the no free lunch theorem tells us that in practice, with finite samples we cannot hope to search for the expected risk minimizer over F ∗ {\displaystyle {\mathcal {F}}^{}} . Thus we often consider a subset of F ∗ {\displaystyle {\mathcal {F}}^{}} , F {\displaystyle {\mathcal {F}}} , to carry out searches on. By doing so, we risk that f ∗ {\displaystyle f^{}} might not be an element of F {\displaystyle {\mathcal {F}}} . This tradeoff can be mathematically expressed as In the above decomposition, part ( b ) {\displaystyle (b)} does not depend on the data and is non-stochastic. It describes how far away our assumptions ( F {\displaystyle {\mathcal {F}}} ) are from the truth ( F ∗ {\displaystyle {\mathcal {F}}^{}} ). ( b ) {\displaystyle (b)} will be strictly greater than 0 if we make assumptions that are too strong ( F {\displaystyle {\mathcal {F}}} too small). On the other hand, failing to put enough restrictions on F {\displaystyle {\mathcal {F}}} will cause it to be not learnable, and part ( a ) {\displaystyle (a)} will not stochastically converge to 0. This is the well-known overfitting problem in statistics and machine learning literature. == Example: Tikhonov regularization == A good example where learnable classes are used is the so-called Tikhonov regularization in reproducing kernel Hilbert space (RKHS). Specifically, let F ∗ {\displaystyle {\mathcal {F^{}}}} be an RKHS, and | | ⋅ | | 2 {\displaystyle ||\cdot ||_{2}} be the norm on F ∗ {\displaystyle {\mathcal {F^{}}}} given by its inner product. It is shown in that F = { f : | | f | | 2 ≤ γ } {\displaystyle {\mathcal {F}}=\{f:||f||_{2}\leq \gamma \}} is a learnable class for any finite, positive γ {\displaystyle \gamma } . The empirical minimization algorithm to the dual form of this problem is arg min f ∈ F ∗ { ∑ i = 1 n L ( f ( x i ) , y i ) + λ | | f | | 2 } {\displaystyle \arg \min _{f\in {\mathcal {F}}^{}}\left\{\sum _{i=1}^{n}L(f(x_{i}),y_{i})+\lambda ||f||_{2}\right\}} This was first introduced by Tikhonov to solve ill-posed problems. Many statistical learning algorithms can be expressed in such a form (for example, the well-known ridge regression). The tradeoff between ( a ) {\displaystyle (a)} and ( b ) {\displaystyle (b)} in (2) is geometrically more intuitive with Tikhonov regularization in RKHS. We can consider a sequence of { F γ } {\displaystyle \{{\mathcal {F}}_{\gamma }\}} , which are essentially balls in F ∗ {\displaystyle {\mathcal {F^{}}}} with centers at 0. As γ {\displaystyle \gamma } gets larger, F γ {\displaystyle {\mathcal {F}}_{\gamma }} gets closer to the entire space, and ( b ) {\displaystyle (b)} is likely to become smaller. However we will also suffer smaller convergence rates in ( a ) {\displaystyle (a)} . The way to choose an optimal γ {\displaystyle \gamma } in finite sample settings is usually through cross-validation. == Relationship to empirical process theory == Part ( a ) {\displaystyle (a)} in (2) is closely linked to empirical process theory in statistics, where the empirical risk { ∑ i = 1 n L ( y i , f ( x i ) ) , f ∈ F } {\displaystyle \{\sum _{i=1}^{n}L(y_{i},f(x_{i})),f\in {\mathcal {F}}\}} are known as empirical processes. In this field, the function class F {\displaystyle {\mathcal {F}}} that satisfies the stochastic convergence are known as uniform Glivenko–Cantelli classes. It has been shown that under certain regularity conditions, learnable classes and uniformly Glivenko-Cantelli classes are equivalent. Interplay between ( a ) {\displaystyle (a)} and ( b ) {\displaystyle (b)} in statistics literature is often known as the bias-variance tradeoff. However, note that in the authors gave an example of stochastic convex optimization for General Setting of Learning where learnability is not equivalent with uniform convergence.
Pharmacy automation
Pharmacy automation involves the mechanical processes of handling and distributing medications. Any pharmacy task may be involved, including counting small objects (e.g., tablets, capsules); measuring and mixing powders and liquids for compounding; tracking and updating customer information in databases (e.g., personally identifiable information (PII), medical history, drug interaction risk detection); and inventory management. This article focuses on the changes that have taken place in the local, or community pharmacy since the 1960s. == History == Dispensing medications in a community pharmacy before the 1970s was a time-consuming operation. The pharmacist dispensed prescriptions in tablet or capsule form with a simple tray and spatula. Many new medications were developed by pharmaceutical manufacturers at an ever-increasing pace, and medications prices were rising steeply. A typical community pharmacist was working longer hours and often forced to hire staff to handle increased workloads which resulted in less time to focus on safety issues. These additional factors led to use of a machine to count medications. The original electronic portable digital tablet counting technology was invented in Manchester, England between 1967 and 1970 by the brothers John and Frank Kirby. I had the original idea of how the machine would work and it was my patent, but it was a joint effort getting it to work in a saleable form. It was 3 years of very hard work. I had originally studied heavy electrical engineering before changing over to Medical School and qualifying as a Medical Doctor in 1968. In fact I was Senior House (Casualty) Officer (A&E or ER) in 1970 at North Manchester General Hospital when I filed the patent. I must have been the only hospital doctor in Britain with an oscilloscope, a soldering iron and a drawing board in his room in the Doctors' Residence. The housekeepers were bemused by all the wires. Frank originally trained as a Banker but quit to take a job with a local electronics firm during the development. He died in 1987, a terrible loss. [Extract from personal communication received in March 2010 from John Kirby.] Frank and John Kirby and their associate Rodney Lester were pioneers in pharmacy automation and small-object counting technology. In 1967, the Kirbys invented a portable digital tablet counter to count tablets and capsules. With Lester they formed a limited company. In 1970, their invention was patented and put into production in Oldham, England. The tablet counter aided the pharmacy industry with time-consuming manual counting of drug prescriptions. A counting machine consistently counted medications accurately and quickly. This aspect of pharmacy automation was quickly adopted, and innovations emerged every decade to aid the pharmacy industry to deliver medications quickly, safely, and economically. Modern pharmacies have many new options to improve their workflow by using the new technology, and can choose intelligently from the many options available. === Chronology === On 1 January 1971 commercial production of the first portable digital tablet counters in the World began. John Kirby had filed U.K. Patent number GB1358378(A) on 8 September 1970 and U.S. patent number 3789194 on 9 August 1971. These early electronic counters were designed to help pharmacies replace the common (but often inaccurate) practice of counting medications by hand. In 1975, the digital technology was exported to America. In early 1980 a dedicated research, development and production facility was built in Oldham, England at a cost of £500,000. Between 1982 and 1983, two separate development facilities had been created. In America, overseen by Rodney Lester; and in England, overseen by the Kirby brothers. In 1987, Frank Kirby died. In 1989, John Kirby moved his UK facility to Devon, England. A simple to operate machine had been developed to accurately and quickly count prescription medications. Technology improvements soon resulted in a more compact model. The price of such equipment in 1980 was around £1,300. This substantial investment in new technology was a major financial consideration, but the pharmacy community considered the use of a counting machine as a superior method compared to hand-counting medications. These early devices became known as tablet counter, capsule counter, pill counter, or drug counter. The new counting technology replaced manual methods in many industries such as, vitamin and diet supplement manufacturing. Technicians needed a small, affordable device to count and bottle medications. In England and America, the 1980s and 1990s saw new the development of high-speed machines for counting and bottle filling, Like their pharmacy-based counterparts, these industrial units were designed to be fast and simple to operate, yet remain small and cost effective. In America, in the late 1990s/early 2000s a new type of tablet counter appeared. It was simple to use, compact, inexpensive, and had good counting accuracy. At the turn of the millennium technical advances allowed the design of counters with a software verification system. With an onboard computer, displaying photo images of medications to assist the pharmacist or pharmacy technician to verify that the correct medication was being dispensed. In addition, a database for storing all prescriptions that were counted on the device. Between September 2005 and May 2007, American Capital made a major financial investment in Kirby Lester, which then relocated to a larger facility to expand its research and development capabilities. This move added extra space for product research and development facility (R&D). It allowed the opportunity to develop new advanced technology products that met the pharmacy's needs for simple, accurate, and cost-effective ways to dispense prescriptions safely. Pictured here is an early American type of integrated counter and packaging device. This machine was a third generation step in the evolution of pharmacy automated devices. Later models held pre-counted containers of commonly-prescribed medications. == Global variations == In the EU member states legislation was introduced in 1998 which had a major effect on UK Pharmacy operations. It effectively prohibited the use of tablet counters for counting and dispensing bulk packaged tablets. Both usage and sales of the machines in the UK declined rapidly as a result of the introduction of blister packaging for medicines. == Current state of the industry == A tablet counter has become a standard in more than 30,000 sites in 35 countries (as of 2010) (including many non-pharmacy sites, such as manufacturing facilities that use a counting machine as a check for small items). During the 1990s through 2012, numerous new pharmacy automation products came to market. During this timeframe, counting technologies, robotics, workflow management software, and interactive voice recognition (IVR) systems for retail (both chain and independent), outpatient, government, and closed-door pharmacies (mail order and central fill) were all introduced. Additionally, the concept of scalability - of migrating from an entry-level product to the next level of automation (e.g., counting technology to robotics) - was introduced and subsequently launched a new product line in 1997. Pharmacists everywhere are making the switch to automation for its increased speed, greater accuracy, and better security. As the industry evolves and customer expectations grow, automation is becoming less of a luxury and more of a necessity. Especially for independent pharmacies, automation is now a means of keeping up with the competition of large chain pharmacies. == Technological changes and design improvements == Constant developments in technology make the dispensing of prescription medications safer, more accurate and more efficient. In America, in 2008, "next-generation" counting and verification systems were introduced. Based on the counting technology employed in preceding models, later machines included the ability to help the pharmacy operate more effectively. Equipped with a new computer interface to a pharmacy management system, with workflow and inventory software. It also included "checks and balances" to ensure the technician and pharmacist were dispensing the correct medication for each patient. This is something that is important to keep reported correctly when dealing with controlled substances like narcotics. This was a step forward to verify all 100% of prescriptions that were dispensed by pharmacy staff. In America, in 2009, further advanced counters were designed that included the ability to dispense hands-free – a feature that many operators had desired. This allowed pharmacies to automate their most commonly dispensed medications via calibrated cassettes. Thirty of a pharmacy's common medications would now be dispensed automatically. Another new model doubled that throughput via an enclosed robotic mechanism. Robo
Behavior informatics
Behavior informatics (BI) is the informatics of behaviors so as to obtain behavior intelligence and behavior insights. BI is a research method combining science and technology, specifically in the area of engineering. The purpose of BI includes analysis of current behaviors as well as the inference of future possible behaviors. This occurs through pattern recognition. Different from applied behavior analysis from the psychological perspective, BI builds computational theories, systems and tools to qualitatively and quantitatively model, represent, analyze, and manage behaviors of individuals, groups and/or organizations. BI is built on classic study of behavioral science, including behavior modeling, applied behavior analysis, behavior analysis, behavioral economics, and organizational behavior. Typical BI tasks consist of individual and group behavior formation, representation, computational modeling, analysis, learning, simulation, and understanding of behavior impact, utility, non-occurring behaviors, etc. for behavior intervention and management. The Behavior Informatics approach to data utilizes cognitive as well as behavioral data. By combining the data, BI has the potential to effectively illustrate the big picture when it comes to behavioral decisions and patterns. One of the goals of BI is also to be able to study human behavior while eliminating issues like self-report bias. This creates more reliable and valid information for research studies. == Behavior == From an Informatics perspective, a behavior consists of three key elements: actors (behavioral subjects and objects), operations (actions, activities) and interactions (relationships), and their properties. A behavior can be represented as a behavior vector, all behaviors of an actor or an actor group can be represented as behavior sequences and multi-dimensional behavior matrix. The following table explains some of the elements of behavior. Behavior Informatics takes into account behavior when analyzing business patterns and intelligence. The inclusion of behavior in these analyses provides prominent information on social and driving factors of patterns. == Applications == Behavior Informatics is being used in a variety of settings, including but not limited to health care management, telecommunications, marketing, and security. Behavior Informatics provides a manner in which to analyze and organize the many aspects that go into a person's health care needs and decisions. When it comes to business models, behavior informatics may be utilized for a similar role. Organizations implement behavior informatics to enhance business structure and regime, where it helps moderate ideal business decisions and situations.